Bio2 Technologies raised $4.3 million for Vitrium, its resorbable orthopedic biomaterial for musculoskeletal surgery, reports Mass Device.
Three things to know:
1. Vitrium enables surgeons to reconstruct bony anatomy and is currently undergoing a clinical trial.
2 The device consists of bioactive glass and features porous, load-bearing and osteoconductive properties.
3. In August, Bio2 enrolled its first index patient in its Vitrium cervical interbody trial and aims to enroll up to 168 participants to compare the cervical implant to allograft.
More articles on devices:
'A dream come true': Dr. Jorge Chahla strives for success at Rush
New York hospital invests $2M in imaging system for spine, brain — 4 things to know
What Stryker's spine division stands to gain from 5 acquisitions